In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Depacon (AbbVie); Depakene (AbbVie); Depakote (AbbVie)
- INDICATIONS: Seizures, migraine
- SYNONYM: valproate sodium; divalproex
- CLASS: Anticonvulsant, Antipsychotic, Mood stabilizer
- HALF-LIFE: 6–16 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amitriptyline, Aspirin, Ceftobiprole, Cholestyramine, Clobazam, Clozapine, Doripenem, Eslicarbazepine, Ethosuximide, Imipenem/Cilastatin/Relebactam, Indinavir, Ivermectin, Lesinurad, Levomepromazine, Lumateperone, Meropenem, Meropenem & Vaborbactam, Olanzapine, Oxcarbazepine, Paliperidone, Risperidone, Rufinamide, Temozolomide, Tipranavir, Topiramate, Topiramate, Vorinostat, Zidovudine, Zinc, Zuclopenthixol
- See adverse reactions attributed to class:
Gestational exposure to valproate is associated with an unacceptably high risk of major congenital malformations, neurodevelopmental disorders, and other adverse outcomes. Prescription of valproate to reproductive-age women is therefore strongly discouraged in many parts of the world.
From January 2024, the United Kingdom began regulating that no one under the age of 55 will be newly prescribed sodium valproate unless two specialists agree that no other effective or tolerable treatment is available, or unless there are "compelling reasons that reproductive risks do not apply" (Medicines and Healthcare Products Regulatory Agency. Date of Issue: 28 November 2023; Reference No: NatPSA/2023/013/MHRA).
LIFE-THREATENING ADVERSE REACTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 01/04/2025
